JRF 101
Alternative Names: JRF-101; JRF-101a; JRF-101b; JRF-101c; JRF-101dLatest Information Update: 28 Jan 2025
Price :
$50 *
At a glance
- Originator Chengdu Jinrui Foundation Biotech
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Glioblastoma; Medulloblastoma; Non-small cell lung cancer; Ovarian cancer
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for phase-I development in Glioblastoma in China (Parenteral, Injection)
- 28 Jan 2025 No recent reports of development identified for phase-I development in Medulloblastoma in China (Parenteral, Injection)
- 28 Jan 2025 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer in China (Parenteral, Injection)